A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants

NCT07528703 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

IPF

Interventions

DRUG: RC010 Inhalation Powder
DRUG: RC010 Inhalation Powder placebo

Sponsor

Nanjing Reju Therapeutics Co., Ltd